1384.0000 48.90 (3.66%)
NSE Jan 19, 2026 09:07 AM
Volume: 105
 

logo
Tatva Chintan Pharma Chem Ltd.
27 Sep 2023, 12:00AM
1384.00
3.66%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Number of FII/FPI investors increased from 19 to 31 in Sep 2025 qtr.
More from Tatva Chintan Pharma Chem Ltd.
Recommended